# Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

> **NCT00406068** · PHASE2,PHASE3 · COMPLETED · sponsor: **Bioniche Life Sciences Inc.** · enrollment: 129 (actual)

## Conditions studied

- Bladder Neoplasms

## Interventions

- **DRUG:** Mycobacterial cell wall-DNA complex

## Key facts

- **NCT ID:** NCT00406068
- **Lead sponsor:** Bioniche Life Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2016-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00406068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00406068, "Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00406068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*